So here's a thing about running clinical trials in 2026: sometimes you just can't find enough people who want to be in them. Pfizer Inc. (PFE) and its German partner BioNTech SE (BNTX) have reportedly hit pause on recruiting for a major U.S. study of their updated COVID-19 vaccine. The target was adults aged 50 to 64, but the sign-up sheet just wasn't filling up.
The companies confirmed they've told the U.S. Food and Drug Administration about the decision. The study was aiming for between 25,000 and 30,000 participants, but it fell short. According to a letter cited by Reuters, Pfizer will also stop monitoring participants for COVID-19 symptoms after April 3. They had already closed enrollment back on March 6 after looking at the latest epidemiological trends.
Regulatory Hurdles and Waning Interest
This isn't just a story about one trial having trouble. It's a snapshot of the broader headwinds now facing COVID-19 vaccine makers. Demand in the U.S. has cooled off, and the regulatory bar has been raised.
Last year, the FDA decided that to get a vaccine approved for the 50–64 age group, you need to run a large, placebo-controlled trial. It's a higher standard. And since that rule came into effect, no COVID-19 vaccines have been cleared for this demographic. Add in lower infection rates and a general decline in public enthusiasm for booster shots, and you've got a perfect storm for making trial recruitment really, really hard.
Meanwhile, in the world of corporate legal battles, BioNTech filed a patent infringement lawsuit against Moderna Inc. (MRNA) back in December 2025. BioNTech alleges that Moderna's next-generation COVID-19 shot, called mNEXSPIKE, relies on technology that BioNTech developed and patented.
A $2 Billion Win in a Different Arena
While one door seems to be closing on the trial front, another one just swung wide open for Pfizer in a courtroom in Europe. In a separate but massive development, a Belgian court has ordered Poland and Romania to pay up for COVID-19 vaccine doses they ordered but then decided not to take.
The Brussels Court of First Instance ruled that Poland must pay roughly 1.3 billion euros and Romania owes about 600 million euros. That's a combined 1.9 billion euros, or around $2.2 billion. This was all under a 2021 contract negotiated with the European Commission.
The court basically said a deal is a deal. It ruled that declining infection rates weren't a good enough reason to change the agreement, and it rejected arguments from the countries about pricing terms and liability clauses.
The Political Aftermath
Both countries had refused to accept delivery of their allocated doses and hadn't paid for them, which is why Pfizer took them to court back in 2023.
The ruling has sparked some political finger-pointing. Polish Prime Minister Donald Tusk publicly blamed his predecessor, Mateusz Morawiecki, for the decisions that led to this hefty penalty. Poland has said it will look for legal ways to fight the ruling, and Romania is expected to give a formal response.
So, to sum up the day for Pfizer and BioNTech: one major clinical trial is on ice because not enough people signed up, but the company just won a legal judgment worth billions in Europe. And the market's reaction? On the day this news came out, Pfizer shares were up 0.94% at $28.34, trading at a new 52-week high. BioNTech shares were up 1.53% at $90.24.
